Leigh Zawel - Aug 23, 2021 Form 4/A - Amendment Insider Report for Cullinan Oncology, Inc. (CGEM)

Role: Officer
Signature: /s/ Jeffrey Trigilio, Attorney-in-Fact
Stock symbol: CGEM
Transactions as of: Aug 23, 2021
Transactions value $: -$815,422
Form type: 4/A - Amendment
Date filed: 8/26/2021, 07:14 PM
Date Of Original Report: Aug 24, 2021
Previous filing: Aug 26, 2021
Next filing: Sep 8, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CGEM	Common Stock	Sale	-$815K	-28.1K	-23.12%	$29.00	93.5K	Aug 23, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.60 to $29.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.60 to $29.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Scientific Officer, Small Molecules This amended Form 4 is being filed to include an explanatory note that the reported sales were made pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.